BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23894305)

  • 1. Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
    Liu Y; Zheng W; Song Y; Ma W; Yin H
    PLoS One; 2013; 8(7):e68442. PubMed ID: 23894305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
    Liu Y; Song Y; Ma W; Zheng W; Yin H
    Leuk Res; 2013 Mar; 37(3):349-56. PubMed ID: 23287430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
    Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
    Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
    Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T
    Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.
    Xishan Z; Ziying L; Jing D; Gang L
    Sci Rep; 2015 Jul; 5():12460. PubMed ID: 26228085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
    Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
    Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
    Bueno MJ; Pérez de Castro I; Gómez de Cedrón M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernández-Piqueras J; Malumbres M
    Cancer Cell; 2008 Jun; 13(6):496-506. PubMed ID: 18538733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
    Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
    Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
    Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
    Asimakopoulos FA; Shteper PJ; Krichevsky S; Fibach E; Polliack A; Rachmilewitz E; Ben-Neriah Y; Ben-Yehuda D
    Blood; 1999 Oct; 94(7):2452-60. PubMed ID: 10498618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
    Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
    Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
    Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
    Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.
    Tedeschi FA; Cardozo MA; Valentini R; Zalazar FE
    Leuk Lymphoma; 2010 May; 51(5):892-6. PubMed ID: 20141430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1.
    Nie ZY; Liu XJ; Zhan Y; Liu MH; Zhang XY; Li ZY; Lu YQ; Luo JM; Yang L
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30962263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.